{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:09:52Z","timestamp":1791047392483,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.leukres.2014.02.007","type":"journal-article","created":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T08:18:37Z","timestamp":1393575517000},"page":"564-568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia"],"prefix":"10.1016","volume":"38","author":[{"given":"William E.","family":"Pierceall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1282-9492","authenticated-orcid":false,"given":"Ryan J.","family":"Lena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno C.","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Doykan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Elashoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Cardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.02.007_bib0005","series-title":"SEER Cancer statistics review, 1975\u20132010","year":"2013"},{"key":"10.1016\/j.leukres.2014.02.007_bib0010","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.02.007_bib0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.02.007_bib0020","series-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u2122) Acute myeloid leukemia. Version 1","year":"2012"},{"key":"10.1016\/j.leukres.2014.02.007_bib0025","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.02.007_bib0030","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2741\/4181","article-title":"Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin","volume":"18","author":"Cowan","year":"2013","journal-title":"Front Biosci"},{"key":"10.1016\/j.leukres.2014.02.007_bib0035","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.leukres.2014.02.007_bib0040","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.leu.2404477","article-title":"The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells","volume":"21","author":"ten Cate","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.02.007_bib0045","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3324\/haematol.2011.055822","article-title":"Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia","volume":"97","author":"Walter","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.02.007_bib0050","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy","volume":"334","author":"Ni Chonghaile","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.leukres.2014.02.007_bib0055","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2014.02.007_bib0060","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1158\/1535-7163.MCT-13-0692","article-title":"BH3 Profiling discriminates response to cytarabine-based treatment of acute myeloid leukemia","volume":"12","author":"Pierceall","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.leukres.2014.02.007_bib0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc2297","article-title":"Diagnosing and exploiting cancer's addiction to blocks in apoptosis","volume":"8","author":"Letai","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.leukres.2014.02.007_bib0070","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria pried by death signals determine cellular addiction to antiapoptotic Bcl-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2014.02.007_bib0075","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.exphem.2009.03.002","article-title":"Deficient activation of Bax and Bak confers resistance to gemtuzumab ozogamicin-induced apoptotoic cell death in AML","volume":"37","author":"Haag","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2014.02.007_bib0080","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/1535-7163.MCT-06-0562","article-title":"Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol\/vorinostat antileukemic interactions","volume":"6","author":"Rosato","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.leukres.2014.02.007_bib0085","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-07-0835","article-title":"Synergistic intereactions between vorinostat and sorafenib in chronic myelogenous leukemic cells involve Mcl-1 and p21CIP1 down-regulation","volume":"13","author":"Dasmahapatra","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.02.007_bib0090","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.02.007_bib0095","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood.V116.21.2191.2191","article-title":"Quantitative effect of age in predicting empirically-defined treatment-related mortality and resistance in newly diagnosed AML: case against age alone as primary determinant of treatment assignment","volume":"116","author":"Walter","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.02.007_bib0100","doi-asserted-by":"crossref","first-page":"12895","DOI":"10.1073\/pnas.0914878107","article-title":"Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes","volume":"107","author":"Ryan","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2014.02.007_bib0155","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1016\/j.bmc.2013.08.017","article-title":"Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker","volume":"21","author":"Richard","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.leukres.2014.02.007_bib0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccr.2013.01.018","article-title":"ABT-199: taking dead aim at BCL-2","volume":"23","author":"Davids","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2014.02.007_bib0115","doi-asserted-by":"crossref","first-page":"9107","DOI":"10.1038\/sj.onc.1207196","article-title":"Induction of apoptosis by enediyne antibiotic calicheamicin thetall proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner","volume":"22","author":"Prokop","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2014.02.007_bib0120","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.bjc.6605922","article-title":"Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types","volume":"103","author":"Green","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2014.02.007_bib0125","doi-asserted-by":"crossref","first-page":"e52753","DOI":"10.1371\/journal.pone.0052753","article-title":"Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression","volume":"7","author":"Barbone","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.leukres.2014.02.007_bib0130","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V91.3.991.991_991_1000","article-title":"Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse","volume":"91","author":"Kaufmann","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.02.007_bib0135","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.02.007_bib0140","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2014.02.007_bib0145","doi-asserted-by":"crossref","first-page":"22899","DOI":"10.1074\/jbc.M113.449926","article-title":"CXCR4 chemokine receptor mechanistic signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak","volume":"288","author":"Kremer","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2014.02.007_bib0150","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/leu.2012.366","article-title":"HDAC inhibition by SNDX-275 (entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML","volume":"27","author":"Zhou","year":"2013","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614000563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614000563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T21:48:44Z","timestamp":1597528124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614000563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0145212614000563"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.02.007","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}